For following the competition: what moved in each program, several studies read as one move.
- pimicotinib
- irpagratinib
- PD-L1 Inhibitor ABSK043
- + 5 more
Mondays · ranked, phase 3 first · readouts ahead · See a sample brief
Add Abbisko Cayman to watchlistEvery Monday by email · turn it off any timePro · free during the beta